Holen Sie sich die Stockscreener-App
0.8293
2.69%
-0.0229
Handel nachbörslich:
.85
0.0207
+2.50%
Schlusskurs vom Vortag:
$0.8522
Offen:
$0.8675
24-Stunden-Volumen:
1.39M
Relative Volume:
0.88
Marktkapitalisierung:
$81.81M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-93.61M
KGV:
-0.393
EPS:
-2.11
Netto-Cashflow:
$-71.16M
1W Leistung:
-15.33%
1M Leistung:
-0.10%
6M Leistung:
-13.32%
1J Leistung:
-37.65%
1-Tages-Spanne:
$0.80
$0.89
1-Wochen-Bereich:
$0.80
$0.985
52-Wochen-Spanne:
$0.561
$2.11
Immunic Inc Stock (IMUX) Company Profile
Firmenname
Immunic Inc
Sektor
Branche
Telefon
(332) 255-9818
Adresse
1200 AVENUE OF THE AMERICAS, NEW YORK
Vergleichen Sie IMUX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
0.8293 | 83.75M | 0 | -93.61M | -71.16M | -2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-25 | Eingeleitet | William Blair | Outperform |
| 2024-11-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-27 | Eingeleitet | B. Riley Securities | Buy |
| 2022-10-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-04-15 | Eingeleitet | Aegis Capital | Buy |
| 2021-03-24 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-10-02 | Eingeleitet | SVB Leerink | Outperform |
| 2020-08-26 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-07 | Fortgesetzt | ROTH Capital | Buy |
| 2020-07-20 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-06-05 | Eingeleitet | Wedbush | Outperform |
| 2020-05-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-25 | Eingeleitet | ROTH Capital | Buy |
| 2019-07-11 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Immunic Inc Aktie (IMUX) Neueste Nachrichten
What are the future prospects of Immunic Inc.July 2025 Intraday Action & Consistent Return Strategy Ideas - thegnnews.com
Immunic (IMUX) Q2 Loss Widens 25% - AOL.com
Momentum Screeners Rank Immunic Inc. in Top 5 TodayCapital Protection Trading Strategies Gain Interest - beatles.ru
H.C. Wainwright reiterates Buy rating on Immunic stock, citing positive MS data - Investing.com
H.C. Wainwright reiterates Buy rating on Immunic stock, citing positive MS data By Investing.com - Investing.com South Africa
Immunic, Inc. Advances Multiple Sclerosis Drug Trials - TipRanks
Immunic, Inc. shares rise 3.21% premarket after Novartis' positive Phase III trial results for ianalumab in Sjögren's disease. - AInvest
William Blair Maintains Immunic(IMUX.US) With Buy Rating - 富途牛牛
Is Immunic Inc. stock a value trapInvestment Timing Signals - mustnews.co.kr
Technical signs of recovery in Immunic Inc.Free Risk-Adjusted Picks With Exit Strategy - Newser
Will Immunic Inc. price bounce be sustainableFree Smart Trade Plans With Risk Protection - Newser
Intraday pattern recognizer results for Immunic Inc.Free Early Entry Tips With Low Risk Zone - Newser
Immunic reports promising Phase 2 data for lead drug candidate in progressive MSICYMI - Proactive financial news
Is a relief rally coming for Immunic Inc. holdersConservative Investment Setup and Risk Analysis - Newser
Immunic: Q2 Earnings Snapshot - Connecticut Post
Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update - The Malaysian Reserve
Small cap wrap: Immunic, Nextech3D.ai, EDM Resources, Alvopetro… - Proactive financial news
Immunic Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Immunic CEO on strong Q2 progress with vidofludimus calcium trials for MS - Proactive financial news
Immunic CEO Discusses Strong Q2 Progress in Vidofludimus Calcium Trials for MS Treatment - AInvest
Immunic advances MS drug program with Phase 3 trials fully enrolled - Proactive financial news
Immunic Advances Phase 3 Trials and Financial Health - TipRanks
Immunic Q2 net loss widens, flags potential cash raise - AInvest
Biotech Immunic Q2 net loss widens, flags need to raise cash - MarketScreener
Immunic, Inc.: A High-Potential Biotech Play in the MS and GI Therapeutics Space - AInvest
EQS-News: Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Ariva
Immunic (IMUX) to Release Quarterly Earnings on Thursday - Defense World
Immunic, Inc. shares fall 1.43% after-hours as ImmunoPrecise Antibodies Ltd. reports earnings miss and auditor raises 'going concern' doubt. - AInvest
Immunic, Inc. shares fall 2.36% premarket after Sonnet BioTherapeutics' clinical trial data shows potential for SON-1010 in ovarian cancer. - AInvest
Immunic Inc. Stock Analysis and ForecastBreakout profit opportunities - Jammu Links News
When is Immunic Inc. stock expected to show significant growthMarket-crushing stock picks - Jammu Links News
How does Immunic Inc. compare to its industry peersMaximize gains with proven stock analysis - Jammu Links News
What is the dividend policy of Immunic Inc. stockMaximize returns with strategic portfolio planning - Jammu Links News
Should I hold or sell Immunic Inc. stock in 2025Invest confidently with real-time data analysis - Jammu Links News
What is the risk reward ratio of investing in Immunic Inc. stockSuperior profit margins - Jammu Links News
What are analysts’ price targets for Immunic Inc. in the next 12 monthsTrack high-yield stocks before they peak - Jammu Links News
What institutional investors are buying Immunic Inc. stockUnstoppable investment returns - Jammu Links News
What drives Immunic Inc. stock priceGain access to exclusive stock analysis - Jammu Links News
Is it the right time to buy Immunic Inc. stockProven strategies for superior portfolio growth - Jammu Links News
Is Immunic Inc. a growth stock or a value stockBuild wealth faster with consistent investment plans - Jammu Links News
Immunic, Inc. (NASDAQ:IMUX) Receives $7.50 Consensus Target Price from Brokerages - Defense World
Published on: 2025-08-03 05:26:52 - Jammu Links News
How volatile is Immunic Inc. stock compared to the marketTurbocharged investment results - Jammu Links News
How Immunic Inc. stock performs during market volatilityAccurate Forecast System with AI Support - Newser
Why is Immunic Inc. stock attracting strong analyst attentionBreakout Stocks Opportunities That Work - Jammu Links News
Finanzdaten der Immunic Inc-Aktie (IMUX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):